We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · January 05, 2022

Once-Daily Risdiplam Shows Benefit for SMA Types 2 and 3

The Lancet Neurology


Additional Info

The Lancet Neurology
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial
Lancet Neurol 2022 Jan 01;21(1)42-52, E Mercuri, N Deconinck, ES Mazzone, A Nascimento, M Oskoui, K Saito, C Vuillerot, G Baranello, O Boespflug-Tanguy, N Goemans, J Kirschner, A Kostera-Pruszczyk, L Servais, M Gerber, K Gorni, O Khwaja, H Kletzl, RS Scalco, H Staunton, WY Yeung, C Martin, P Fontoura, JW Day

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading